Global /Australia /Healthcare /Drug Manufacturers - General /ACR
chevron_leftBack
Acrux Ltd. logo

Acrux Ltd.

ACR
ASX: ACR Delayed
0.0120AUD 9.1%
0.0085 USD
As of 7 June 2026, Acrux Ltd. has a market cap of $3.22M USD, ranking #45933 globally and #1693 in Australia. It ranks #4070 in the Healthcare sector, and #1301 in the Drug Manufacturers - General industry.
Global Rank
45933
Country Rank
1693
Sector Rank
4070
Industry Rank
1301
Key Stats
Market Cap
$3.22MUSD
4.52M AUD
Enterprise Value
$4.06MUSD
5.77M AUD
Revenue (TTM)
$2.01MUSD
2.81M AUD
EBITDA (TTM)
-$3.9MUSD
-5.53M AUD
Net Income (TTM)
-$1.68MUSD
-2.36M AUD
EBITDA Margin
-197%
Profit Margin
-84%
PS Ratio
1.6
PB Ratio
3.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
John Warmbrunn open_in_new
Employees
43
Founded
1998
Website
acrux.com.au open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
9.1% -7.7% -8.3% -21% -15% -52%

News

Loading...

Markets

Exchange Ticker Price
Australian Securities Exchange
MIC: XASX
PRIMARY
ACR
Acrux Ltd
ISIN: AU000000ACR3
Shares Out.:
522.284M1 Shares Float: 482.357M2
TV:
SA:
YF:
GF:
BA:
ACR
MS:
0.0120 AUD
OTC Markets
MIC: OTCM
ARUXF
Acrux Ltd
ISIN: AU000000ACR3
Shares Out.:
409.264M1 Shares Float: 377.977M2
TV:
SA:
YF:
GF:
BA:
MS:
0.0080 USD
Frankfurt Stock Exchange
MIC: XFRA
FJY
Acrux Ltd
ISIN: AU000000ACR3
TV:
SA:
YF:
GF:
BA:
FJY
MS:
0.0015 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Acrux Ltd.

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Similar Companies

Industry: Drug Manufacturers - General (Australia)
Name
Market Cap diff.
PE
$22.82B
31.98B AUD
708K%
52.3
$926.22M
1.3B AUD
29K%
-
$346.24M
485.18M AUD
11K%
-
$335.4M
469.99M AUD
10K%
14.5
$216.39M
303.23M AUD
7K%
-
$166.4M
233.18M AUD
5K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
24M%
38.1
JNJ
$547.28B
17M%
26.4
ABBV
$360.63B
11M%
97.4
$324.68B
256.25B CHF
10M%
19.9
AZN
$289.43B
215.59B GBP
9M%
27.6
NOVN
$277.35B
218.9B CHF
9M%
20.5
chevron_leftBack